Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) EBT (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed EBT for 10 consecutive years, with -$47.5 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 9.58% to -$47.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$196.0 million, a 24.66% increase, with the full-year FY2025 number at -$196.0 million, up 24.67% from a year prior.
  • EBT was -$47.5 million for Q4 2025 at Rhythm Pharmaceuticals, up from -$52.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$31.8 million in Q2 2024 to a low of -$141.1 million in Q1 2024.
  • A 5-year average of -$49.5 million and a median of -$44.6 million in 2021 define the central range for EBT.
  • Peak YoY movement for EBT: crashed 170.5% in 2024, then surged 64.97% in 2025.
  • Rhythm Pharmaceuticals' EBT stood at -$50.9 million in 2021, then increased by 16.44% to -$42.5 million in 2022, then grew by 2.49% to -$41.4 million in 2023, then fell by 4.69% to -$43.4 million in 2024, then dropped by 9.58% to -$47.5 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's EBT are -$47.5 million (Q4 2025), -$52.8 million (Q3 2025), and -$46.3 million (Q2 2025).